This pivotal study, designated as Alliance A092204, explores the synergistic potential of cabozantinib and cemiplimab in halting or reversing the progression of ACC. Cabozantinib, an orally administered tyrosine kinase inhibitor (TKI), impedes cellular signaling pathways that promote cancer cell proliferation by targeting receptors involved in tumor growth and angiogenesis. Cemiplimab is a monoclonal antibody functioning as a programmed death receptor-1 (PD-1) immune checkpoint inhibitor, reinvigorating the immune system’s capacity to detect and destroy malignant cells. The rationale behind combining these agents lies in their complementary mechanisms of action, which may collectively enhance anti-tumor efficacy beyond what each drug can achieve individually.

Adrenocortical carcinoma is an uncommon neoplasm arising from the adrenal glands, which are located atop the kidneys and play a critical role in hormone production and regulation. Although adrenal tumors are relatively frequent, with incidental findings in approximately 10% of individuals undergoing imaging for other reasons, the vast majority of these lesions are benign and clinically insignificant. ACC, however, manifests as a highly malignant entity with an incidence estimated at about one person per million annually in the United States. The disease is often detected at advanced stages, rendering traditional interventions largely ineffective and underscoring the necessity for innovative therapeutic strategies.

Participants enrolled in this randomized controlled trial will be allocated to one of two treatment arms. The control arm receives cabozantinib monotherapy; this TKI exerts its anti-cancer effects primarily by inhibiting MET and VEGFR2 kinase activity, thereby disrupting tumor cell signaling and tumor-associated angiogenesis. The investigational arm receives a combination regimen of cabozantinib plus cemiplimab, the latter delivering systemic immunomodulation by lifting immune checkpoint blockade, allowing cytotoxic T-cells to more effectively target tumor cells. Researchers hypothesize that this combination may provoke a more robust tumor response due to the augmented immune-mediated attack coupled with the inhibition of oncogenic signaling.

Treatment durations in the study are planned for up to 24 months contingent upon evidence of clinical benefit and manageable adverse events. Efficacy endpoints include progression-free survival (PFS), which measures the time patients remain free from disease worsening, and overall survival (OS), reflecting the length of time patients live following treatment initiation. Tumor response rates and durability of response will be assessed using standardized imaging and clinical criteria. Safety profiles will be rigorously monitored to detect potential toxicities stemming from each agent alone or their combined administration.

Dr. Bhavana Konda, MD, MPH, Section Chief of Neuroendocrine Tumors and Endocrine Medical Oncology at The Ohio State University Comprehensive Cancer Center and chair of the study, emphasizes the critical nature of this investigation. She notes, “Few effective treatments exist for this devastating cancer. By probing the combination of targeted therapy and immunotherapy, this trial endeavors to enhance disease control and quality of life for patients facing this formidable diagnosis.” Her leadership exemplifies the commitment to advancing therapeutic horizons in oncology, particularly for rare tumor types neglected by prior research efforts.

The underlying biology of ACC involves aberrant cell signaling pathways that drive unchecked tumor growth and metastatic potential. Tyrosine kinase enzymes such as MET and VEGFR2 are instrumental in modulating cell proliferation, migration, and angiogenesis. Meanwhile, tumor cells often evade immune surveillance through upregulation of PD-1/PD-L1 checkpoint pathways that suppress T-cell activity. Combining a TKI with a PD-1 inhibitor therefore offers a compelling dual-pronged approach: blocking tumor-promoting signals while simultaneously unleashing an anti-tumor immune response.

Challenges in treating ACC are multifaceted, including the tumor’s intrinsic resistance to chemotherapy and radiotherapy, as well as its capacity for rapid dissemination. The paucity of patient populations for clinical research further complicates trial design and recruitment. Hence, the Alliance’s effort is especially noteworthy given its extensive network of oncology specialists and research infrastructure, which enables the aggregation of sufficient data to rigorously evaluate this innovative therapeutic concept in a rare disease context.

The investigational agent cemiplimab serves as a groundbreaking immunotherapy approved for multiple cancers, demonstrating durable responses by interrupting immune checkpoints that tumor cells exploit to avoid immune destruction. Its integration into ACC treatment paradigms marks a transformative step, potentially redefining standard care for a malignancy long underserved by modern oncology advances. Concurrently, cabozantinib’s inhibitory activity on multiple kinases offers the promise of targeting redundant signaling pathways crucial for ACC survival and progression.

By measuring outcomes including PFS, OS, tumor regression, and treatment-related adverse effects, this trial aims to delineate not only the clinical benefit but also the safety and tolerability of the drug combination. Data generated will provide insights that may inform future treatment guidelines, influence regulatory approval processes, and inspire subsequent trials incorporating other immunotherapeutic or targeted agents, ultimately contributing to personalized oncology strategies for ACC patients.

In summary, the Alliance A092204 study epitomizes a pioneering effort to surmount the therapeutic challenges posed by advanced adrenocortical carcinoma. Through a scientifically rational combination of cabozantinib and cemiplimab, this trial holds the potential to extend survival, ameliorate symptoms, and improve life quality for individuals afflicted by this rare and lethal cancer. It exemplifies the power of collaborative oncological research to innovate and bring hope where treatment options have traditionally been scarce.

Subject of Research: People
Article Title: Not provided
News Publication Date: Not provided
Web References: Alliance A092204 Clinical Trial
References: Alliance A0922014/NCT06900595 – Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer.
Image Credits: Courtesy The Ohio State University
Keywords: Clinical trials, Medical treatments, Antibody therapy, Immunotherapy, Drug studies, Clinical medicine, Cancer immunotherapy, Tyrosine kinase inhibitors, Cabozantinib, Cemiplimab, Adrenocortical carcinoma, Oncology, Tumor growth, Tumor regression

Head and neck squamous cell carcinoma represents a biologically heterogeneous group of malignancies arising from the mucosal linings of the oral cavity, pharynx, and larynx. Despite advances in multimodal treatment strategies—including surgery, radiation, and chemotherapy—patients with locally advanced disease often face poor prognoses, mainly due to high rates of recurrence and distant metastasis. This pressing clinical challenge has necessitated the exploration of novel neoadjuvant therapies that not only shrink tumors preoperatively but also modulate the tumor immune microenvironment to prevent disease progression.

The phase 2 trial, designated as neoCHANCE-1, was meticulously designed to assess the safety, tolerability, and efficacy of neoadjuvant administration of tislelizumab in combination with afatinib. Tislelizumab is a monoclonal antibody that selectively blocks PD-1, a checkpoint receptor that tumors exploit to evade immune surveillance. By inhibiting PD-1, tislelizumab rejuvenates exhausted T cells, thereby promoting robust antitumor immunity. Afatinib, on the other hand, irreversibly inhibits EGFR, a receptor often overexpressed or mutated in HNSCC, leading to disrupted downstream signaling pathways responsible for tumor cell proliferation and survival.

The trial enrolled patients diagnosed with stage III or IV HNSCC who were eligible for surgical resection. Participants received a neoadjuvant regimen comprising intravenous tislelizumab and oral afatinib over a defined treatment window prior to surgery. The study’s primary endpoints focused on assessing pathological response rates, including the degree of residual viable tumor cells, while secondary endpoints evaluated disease-free survival, overall survival, and safety profiles.

Preliminary results from neoCHANCE-1 have illustrated a compelling improvement in pathological complete response (pCR) rates compared to historical controls treated with standard therapies. Notably, the combinatorial regimen demonstrated pronounced tumor downsizing, facilitating less extensive surgeries and potentially sparing critical anatomical structures. Such outcomes hold profound implications for functional preservation and quality of life, which are pivotal concerns in head and neck oncology.

Mechanistically, afatinib’s inhibition of EGFR not only hampers tumor proliferation programs but also induces immunogenic cell death, releasing tumor antigens that prime immune responses. When used concurrently with PD-1 blockade via tislelizumab, this antigenic surge catalyzes amplified cytotoxic T cell infiltration into the tumor microenvironment. This interplay underscores a critical synergy wherein targeted molecular therapies enhance the efficacy of immunotherapy through modulation of tumor-host immune dynamics.

Further immune profiling of patient tumor biopsies revealed elevated expression of interferon-gamma related genes post-treatment alongside an increase in CD8+ T cell populations, hallmark indicators of an activated antitumor immune milieu. These findings corroborate the hypothesis that neoadjuvant combination therapies can recalibrate immunosuppressive networks, potentially overcoming resistance mechanisms borne out by checkpoint monotherapies.

Safety evaluations indicated that the combined therapeutic regimen was generally well tolerated. Adverse events observed were consistent with known toxicities associated with EGFR inhibition, such as manageable skin rash and diarrhea, and immune-related adverse events typical for checkpoint blockade, including transient fatigue and mild inflammatory reactions. Crucially, no unexpected grade 4 or 5 toxicities were reported, affirming the regimen’s suitability for preoperative administration.

The translational potential of neoCHANCE-1’s findings is extensive. This trial pioneers a clinically actionable paradigm that leverages precision immunomodulation to convert an immunogenically ‘cold’ tumor microenvironment into a ‘hot’ one, thus enhancing surgical candidacy and long-term tumor control. These outcomes not only inspire integration of combined immunotherapy and targeted agents in HNSCC but also suggest avenues for similar strategies in other solid tumor malignancies characterized by EGFR dysregulation and immune evasion.

As immuno-oncology continues to evolve at an unprecedented pace, the integration of multifaceted biological insights into rational drug combinations becomes imperative. NeoCHANCE-1 exemplifies such translational synergy, combining molecular targeting and immune reactivation in a temporally optimized neoadjuvant setting. Future investigations are warranted to validate these findings in larger, multicenter randomized trials and to explore biomarkers predictive of response and resistance.

The trial’s success also beckons exploration of sequential or maintenance therapies post-surgery to consolidate immune-mediated tumor surveillance. Moreover, optimizing dosing schedules, managing immune-related adverse events proactively, and understanding long-term effects on immune memory remain pivotal research priorities.

Given the aggressive nature of locally advanced HNSCC and the historical stagnation in therapeutic innovation, the neoCHANCE-1 trial heralds a new dawn. By reimagining neoadjuvant treatment through the lens of immune and molecular synergy, this approach promises to rewrite the clinical narrative for patients facing a daunting diagnosis.

In summary, the convergence of PD-1 immune checkpoint blockade with EGFR inhibition via tislelizumab and afatinib respectively, administered prior to surgery, manifests a potent antitumor strategy in locally advanced head and neck squamous cell carcinoma. The phase 2 neoCHANCE-1 trial’s encouraging efficacy and manageable safety profile underscore the transformative potential of this therapeutic alliance, setting the stage for enhanced survival and preservation of function in a highly vulnerable patient subset.

As the oncology community eagerly awaits further data, this study undoubtedly propels neoadjuvant immunotherapy combined with targeted inhibition into the spotlight, marking a significant milestone in precision cancer medicine. The implications for patient care transcend HNSCC, potentially informing treatment frameworks across diverse malignancies where immune escape and aberrant receptor signaling coalesce to fuel tumor growth.

Subject of Research: Neoadjuvant combination immunotherapy and targeted therapy for locally advanced head and neck squamous cell carcinoma.

Article Title: Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.

Article References:
Wei, Zg., Chen, Hj., Wang, Dj. et al. Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial. Nat Commun 16, 8918 (2025). https://doi.org/10.1038/s41467-025-63978-y

Image Credits: AI Generated

Non-small cell lung cancer, constituting the majority of lung cancer diagnoses, remains a formidable adversary due to its heterogeneity and typically late-stage presentation. Immune checkpoint inhibitors (ICIs) have revolutionized treatment paradigms, yet predicting patient response and survival remains elusive. Against this backdrop, metabolic imaging using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) emerges as a non-invasive approach that captures tumor glycolytic activity and burden—parameters that may reflect tumor aggressiveness and potential treatment resistance.

The retrospective study analyzed a cohort of 70 patients with stage III or IV NSCLC, all of whom underwent FDG-PET/computed tomography prior to initiation of first-line ICI–based combination therapy. The focus was on quantifying three primary metabolic metrics across all detectable lesions confined to the torso: maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). These indices were employed not only to delineate tumor burden but also to explore their prognostic significance.

A notable aspect of the study was the emphasis on MTV and TLG, volumetric measurements representing the metabolically active tumor volume and lesion glycolytic activity, respectively. Unlike SUVmax, which captures peak glucose uptake in the tumor but may not account for tumor heterogeneity, volumetric parameters potentially provide a more holistic view of disease burden and metabolic aggressiveness.

In univariate analyses, Eastern Cooperative Oncology Group performance status (PS), MTV-torso, and TLG-torso showed significant associations with both progression-free survival (PFS) and overall survival (OS). Performance status, a clinical measure evaluating a patient’s ability to perform ordinary tasks, understandably impacts prognosis. However, the coupling of this clinical index with volumetric PET parameters strengthens the predictive framework, suggesting that combining metabolic imaging with clinical features enhances risk stratification accuracy.

The multivariate models further distilled MTV-torso and PS as independent prognostic biomarkers. Patients exhibiting lower tumor metabolic volumes within the torso experienced substantially prolonged survival durations, with mean PFS extending to over 580 days compared to less than 160 days for their counterparts with higher MTV-torso values. Likewise, overall survival nearly quadrupled for those with lower metabolic tumor burden. Such stark contrasts underscore the power of MTV-torso as a prognostic indicator, reinforcing its potential integration into clinical decision-making algorithms.

Interestingly, SUVmax-torso failed to demonstrate a significant correlation with survival outcomes in this cohort. This finding aligns with emerging evidence cautioning against sole reliance on maximum uptake values, which may overlook the intricate spatial and metabolic heterogeneity of tumor masses. Consequently, the study advocates for increased emphasis on volumetric parameters when leveraging FDG-PET data for prognostication.

The clinical implications of these findings are profound. By incorporating MTV-torso assessments into routine FDG-PET analyses for NSCLC patients slated for combined immunotherapy and chemotherapy, clinicians might better identify individuals at higher risk of disease progression and mortality. This prognostic enrichment could, in turn, guide personalized therapeutic intensification, closer monitoring protocols, or enrollment into clinical trials exploring novel agents.

Moreover, the focus on torso-based lesions—encompassing primary tumors and metastatic deposits within the chest, abdomen, and pelvis—reflects a realistic appraisal of disease dissemination patterns in advanced NSCLC. The metabolic tumor burden within this anatomical region serves as a representative surrogate for overall tumor load, streamlining imaging assessment and optimizing prognostic utility.

The methodology employed in this research is notable for its rigorous quantitative image analysis, providing replicable and objective metrics that transcend subjective interpretations. Utilizing Cox proportional hazards regression and Kaplan-Meier survival estimates ensured robust statistical assessments, enhancing the reliability of conclusions drawn. The retrospective design, while typical for such exploratory investigations, sets the stage for prospective validation studies to cement clinical applicability.

Beyond immediate prognostication, the study’s revelations about FDG-PET volumetric parameters may inspire further exploration into their role as predictive biomarkers for immunotherapy responsiveness. As the landscape of NSCLC treatment evolves, uncovering imaging correlates of immune activation or resistance could revolutionize patient selection and therapeutic tailoring, maximizing benefits while minimizing unnecessary toxicity.

This research also serves as a testament to the synergetic potential of multi-disciplinary collaboration, intertwining nuclear medicine, oncology, radiology, and biostatistics to unravel complex biological phenomena. The precision measurement of metabolic tumor burden unveils previously underappreciated dimensions of NSCLC biology, fostering a nuanced understanding capable of driving clinical innovation.

As we stride deeper into the era of personalized medicine, the integration of advanced imaging biomarkers like MTV-torso alongside molecular and genomic profiling promises to refine prognostic models substantially. The capacity to stratify patients not only on histopathological grounds but also on spatial and metabolic tumor characteristics heralds a future where therapies are meticulously calibrated to individual disease landscapes.

While challenges remain, including the need for standardized imaging protocols, harmonization of volumetric PET metrics across centers, and longitudinal validation, the promising results reported by Obata et al. undoubtedly galvanize the oncology community. These findings illuminate a path toward enhanced prognostic precision in advanced NSCLC, leveraging routinely acquired imaging data to inform pivotal clinical decisions.

In conclusion, the study convincingly positions torso-metabolic tumor volume measured by FDG-PET as a critical prognostic biomarker in patients with advanced non-small cell lung cancer undergoing first-line immunotherapy and chemotherapy. By transcending conventional metabolic metrics and focusing on holistic volumetric parameters, this research pioneers actionable insights that could transform patient management and outcomes in this formidable disease.

Subject of Research: Metabolic tumor burden assessment via FDG-PET as prognostic biomarkers in advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.

Article Title: Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.

Article References:
Obata, T., Norikane, T., Manabe, Y. et al. Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy. BMC Cancer 25, 1454 (2025). https://doi.org/10.1186/s12885-025-14873-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14873-8

Surgical excision with curative intent (R0 resection) has long been considered the cornerstone of treatment in early-stage lung cancer, yet it fails to fully eliminate the threat of disease progression. NSCLC, representing the majority of lung cancer cases, retains a formidable risk of recurrence, which continues to drive significant cancer-related mortality worldwide. This clinical challenge underscores the urgent need for innovative adjuvant strategies designed to eradicate residual microscopic disease and enhance long-term survival outcomes.

The NADIM ADJUVANT trial stands out as the first randomized Phase III study to rigorously evaluate the addition of nivolumab, a PD-1 immune checkpoint inhibitor, to standard platinum-doublet chemotherapy in the adjuvant setting. Building upon encouraging perioperative data from the precursor NADIM and NADIM II trials, this study explores whether continued immunotherapeutic pressure following definitive surgery and chemotherapy can sustain antitumor immune responses and prevent recurrence.

Between January 2021 and December 2022, a total of 206 patients across 30 Spanish hospitals were enrolled and randomized in a 1:1 ratio. Participants in the control arm received adjuvant chemotherapy consisting of carboplatin dosed at an area under the curve (AUC) of 5 combined with paclitaxel at 200 mg/m² administered on a tri-weekly schedule for four cycles, followed by observation only. The experimental group received identical chemotherapy followed by concomitant administration of nivolumab at 360 mg every three weeks during four chemotherapy cycles, and subsequent maintenance nivolumab at 480 mg every four weeks for six additional cycles.

The primary endpoint of this pivotal trial was disease-free survival (DFS), a critical measure reflecting the length of time patients remain free from detectable tumor recurrence following treatment. Secondary endpoints included overall survival (OS) and comprehensive safety assessments to monitor treatment-related toxicities. Additionally, the study incorporated cutting-edge monitoring of minimal residual disease (MRD) via circulating tumor DNA (ctDNA) analysis, employing the Guardant Reveal platform to sensitively detect subclinical tumor burden after surgery.

Mariano Provencio, MD, PhD, the study’s lead investigator from Hospital Universitario Puerta de Hierro Majadahonda, revealed that after a median follow-up of 34 months, median DFS had not yet been reached in either treatment arm, indicating durable responses. Notably, the first quartile of DFS was significantly prolonged in the experimental arm at 30.98 months compared with 17.01 months in the control group. The three-year relapse incidence further underscored the benefit, with only 26.7% of patients in the nivolumab plus chemotherapy arm experiencing recurrence versus 40.1% in patients receiving chemotherapy alone.

A vital component of the study was the exploration of MRD as a prognostic biomarker. Postoperative detection of MRD was strongly associated with inferior DFS outcomes in the experimental cohort, with a hazard ratio of 5.7 and a statistically significant p-value of 0.045. These results affirm the critical role of sensitive ctDNA-based MRD assessment in stratifying patients’ risk profiles and tailoring postoperative therapeutic approaches more precisely.

While augmenting adjuvant chemotherapy with nivolumab demonstrated clear efficacy, safety profiles remained an essential consideration. Grade 3 or higher treatment-related adverse events occurred in 26.2% of patients receiving the combined regimen, compared to 14.5% in the control arm during the adjuvant phase. This indicates that while immune-related toxicities are more common with the addition of nivolumab, they remain manageable and within acceptable limits given the potential clinical benefit.

Dr. Provencio emphasized, “The interim findings from the NADIM ADJUVANT trial offer compelling evidence that incorporating nivolumab into adjuvant chemotherapy regimens can substantially reduce recurrence risk in patients with completely resected stage IB to IIIA NSCLC. These data not only build upon prior perioperative trials but also pave a path forward for integrating immunotherapy into the standard adjuvant treatment paradigm.” He further highlighted the necessity of continued follow-up to robustly define the long-term survival impact and confirm durable remission benefits.

These results resonate deeply within the lung cancer research community, as they provide concrete evidence from a randomized Phase III trial endorsing adjuvant immunotherapy’s role beyond advanced and unresectable disease stages. The implications extend to refining clinical guidelines, optimizing patient selection, and advancing personalized medicine by incorporating MRD and other biomarkers into postoperative care.

The trial’s success also reaffirms the potential of immune checkpoint blockade to engage and sustain antitumor immunity in micrometastatic disease settings where traditional treatments fall short. This aligns with the broader paradigm shift towards leveraging the host’s immune system to achieve durable tumor control and potentially cure in earlier disease stages.

In addition to its clinical impact, the NADIM ADJUVANT study exemplifies collaborative research excellence, uniting a broad network of Spanish hospitals and specialists who collectively endeavored to address a critical unmet need. Their shared commitment culminates in data that will influence global clinical practice and inspire further research to build upon these foundational findings.

As the oncology community awaits final primary endpoint results and longer-term overall survival data, the NADIM ADJUVANT findings signal a watershed moment in the adjuvant management of NSCLC. They herald a future where integrated multimodal treatment strategies incorporating surgery, chemotherapy, immunotherapy, and biomarker-driven monitoring become the standard for improving patient prognosis.

The International Association for the Study of Lung Cancer (IASLC) continues to foster pivotal dialogues and disseminate groundbreaking discoveries such as these during its annual World Conference on Lung Cancer (WCLC). This gathering remains the premier global forum for accelerating advancements in understanding and treating lung and thoracic malignancies through multidisciplinary collaboration.

In summary, the NADIM ADJUVANT Phase III trial advances the field of thoracic oncology by demonstrating that the addition of nivolumab to adjuvant chemotherapy significantly improves disease-free survival outcomes while maintaining an acceptable safety profile in completely resected stage IB–IIIA NSCLC. The integration of MRD testing further enhances the precision of postoperative management. These results promise to transform clinical practice and improve survival for thousands of patients worldwide confronting early-stage lung cancer.

Subject of Research: Adjuvant chemo-immunotherapy in completely resected stage IB–IIIA non-small cell lung cancer (NSCLC)

Article Title: Interim Results from the NADIM ADJUVANT Phase III Trial Indicate Significant Benefit of Nivolumab Addition to Chemotherapy in Reducing Recurrence of Early-Stage NSCLC

News Publication Date: September 8, 2025

Web References:
https://www.iaslc.org/

Keywords: Lung cancer, Non-small cell lung cancer (NSCLC), Adjuvant therapy, Chemo-immunotherapy, Nivolumab, Disease-free survival, Minimal residual disease, ctDNA, Phase III clinical trial, NADIM ADJUVANT, Immunotherapy, Oncology